Related Experiment Video
Updated: Jan 5, 2026
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
[Effect of eIF4E on Autophagy of CD138+ Cells in Multiple Myeloma]
1Shanxi Medical University;Taiyuan 030000, Shanxi Province，China,Department of Hematology,The Second Affiliated Hospital of Shanxi Medical University,Taiyuan 030000, Shanxi Province，China.
Objective:
To investigate the effect of eukaryotic translation initiation factor 4E(eIF4E) on the autophagy of CD138+ plasma cells in multiple myeloma(MM).
Methods:
Multiple myeloma CD138+ plasma cells were treated with eIF4E inhibitor 4EGI, the changes of autophagy-related factors LC3-II and Beclin1 were detected by fluorescent quantitative PCR and Western blot, the changes of cell proliferation inhibition were detected by MTT assay, and cell apoptosis was detected by flow cytometry.
Results:
Quantitative fluorescence PCR showed that after treatment of myeloma cells with 4EGI, the expression levels of LC3-II and Beclin1 mRNA gradually increased with the enhancomer of 4EGI concentration and the prolongation of action time, and the differences were statistically significant (48 h: LC3-Ⅱ,r=0.942, Beclin1,r=0.952; 80 μg/ml: LC3-Ⅱ,r=0.966, Beclin1,r=0.998）; Western blot showed that with the enhancement of 4EGI concentration, the expression of LC3-II and Beclin1 protein gradually increased（LC3-Ⅱ,r=0.923, Beclin1,r=0.977）; CCK-8 showed that the inhibition rate of cells gradually increased （r=0.996）; the apoptotic rate of 4EGI-treated groups (23.23±4.47, 7.59±1.67, 2.03±0.19) was significantly different from that of control group (0.03±0.04) (P<0.05).
Conclusion:
The inhibition of eIF4E can activate the autophagy of CD138+ plasma cells in multiple myeloma and induce the death of myeloma cells.
Insights
Inhibiting eukaryotic translation initiation factor 4E (eIF4E) activates autophagy in multiple myeloma plasma cells. This process leads to increased cell death, offering a potential therapeutic strategy for multiple myeloma.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Multiple myeloma (MM) is a cancer of plasma cells.
- Autophagy plays a complex role in MM, potentially promoting survival or cell death.
- eIF4E is a key regulator of protein synthesis, implicated in cancer progression.
Purpose of the Study:
- To investigate the role of eIF4E in regulating autophagy in CD138+ plasma cells from MM patients.
- To determine if inhibiting eIF4E affects autophagy and myeloma cell viability.
Main Methods:
- CD138+ plasma cells from MM patients were treated with an eIF4E inhibitor (4EGI).
- Autophagy markers (LC3-II, Beclin1) were assessed using quantitative PCR and Western blot.
- Cell proliferation inhibition was measured by MTT assay, and apoptosis by flow cytometry.
Main Results:
- 4EGI treatment significantly increased the mRNA and protein expression of autophagy markers LC3-II and Beclin1 in a dose- and time-dependent manner.
- The eIF4E inhibitor markedly enhanced myeloma cell proliferation inhibition and induced significant apoptosis compared to control groups.
- Statistical analysis confirmed significant correlations between 4EGI concentration/treatment time and the observed changes.
Conclusions:
- Inhibition of eIF4E effectively activates autophagy in CD138+ multiple myeloma plasma cells.
- Targeting eIF4E with inhibitors like 4EGI can induce myeloma cell death, suggesting a potential therapeutic approach for multiple myeloma.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:18Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...